Stellate Ganglion Block in Complex Regional Pain Syndrome
ConditionStellate Ganglion Block
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAnkara City Hospital Bilkent
About this trial
The aim was to investigate the effect of Stellate Ganglion Blockade, which will be applied in addition to conventional physical therapy, on pain and functionality in patients with poststroke complex regional pain syndrome.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Volunteer male and female patients aged 18-75
Diagnosed with Complex Regional Pain Syndrome according to the IASP 2012 Diagnostic Criteria
Patient's pain level must be VAS >4
Disqualifiers
Presence of existing neurological diseases other than rheumatic diseases and stroke
General impairment
Conditions that would constitute a contraindication to application, such as an open wound or sensory deficit in the application area
Presence of active infection
Trial design
Design model
Parallel
Treatments tested in this trial
Stellate Ganglion Block
Procedure/SurgeryThe stellate ganglion is located in front of the anterior tubercle of the C6 vertebra. An ultrasound-guided intervention will be performed from the affected side and 2 cc of 1% lidocaine will be injected.
Treatment groups
32 Participants
are divided into 2 treatment groupsGroup A: Stellat GroupActive comparator 1 intervention
Group B: Only Physical Therapy GroupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Visual Analog Scale (VAS)
Ten-cm VAS was used as a self-report measure for lower back pain intensity. Self reported pain measurement score is between 0-10 and higher scores indicates higher pain severity.
Time frame
Before treatment, 2 weeks and 12 weeks after the end of sessionsSecondary outcomes
1
Brunnstroom stages of stroke recovery (BSSR)
The BSSR is used to evaluate the motor development of the hemiplegic upper extremity, lower extremity and hand in stroke patients using a staging system from 1 (flask) to 6 (normal motor function).
Time frame
before treatment, 2 weeks and 12 weeks after the end of the therapy sessions2
Fugl-Meyer Upper Extremity (FMUE) Scale
The FMUE scale is a stroke- specific, performance-based measure of sensory motor impairment consisting of 33 items, each scored on a scale of 0 to 2. Higher scores signify a lower level of impairment.
Time frame
before treatment, 2 weeks and 12 weeks after the end of the therapy sessions3
Stroke Specific Quality of Life scale (SS-QOL).
The SS-QOL is a questionnaire used to evaluate independence in ADL in patients with stroke, social role within the family and community and quality of life (QOL). It consists of 49 questions scored between one and five giving a total score between 49 and 245. Higher scores indicate better QOL.
Time frame
before treatment, 2 weeks and 12 weeks after the end of the therapy sessionsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov